Chromocell invites individuals, institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19 ...

公司概况 - 公司于2024年2月完成首次公开发行,募集资金约5.7百万美元[173] - 公司主要通过一系列来自Chromocell Holdings的现金垫款、许可安排、桥贷和票据发行以及国立卫生研究院的补助金来为其运营提供资金[202] - 公司完成首次公开发行后进行了一系列交易,包括实施反向股票拆分、优先股转换为普通股、可转换票据自动转换为普通股、向投资者发行新股等[206] - 公司于2024年7月签订了一项总额最高3000万美元的股权融资协议,由投资者根据公司的要求购买公司普通股[208] 研发管线 - 公司正在开发两个基于同一种专有分子的疼痛治疗项目[157] - 公司已完成4期1期临床试验,结果显示CC8464总体耐受性良好,未发现肝肾毒性、中枢神经系统变化和心血管异常,但可能会引起某些患者皮疹[159] - 公司计划启动一项缓慢剂量递增研究,以进一步评估皮疹发生率,预计将于2024年第三季度开始首次给药[160,161] - 公司计划于2025年启动2a期临床试验,评估CC8464在EM和iSFN患者中的潜在疗效[163,164] - 公司估计EM和iSFN在美国的潜在患者群体分别为5,000-50,000人和20,000-80,000人[165] - 公司还启动了一个名为CT2000的新项目,用于治疗急性和慢性眼痛,预计于2025年开始临床试验[167,169] - 公司预计眼部疼痛的潜在患者群体很大,包括每年约500万例角膜擦伤等[168] - 公司可能会在未来进一步拓展管线,但目前其他内部发现的化合物仍处于临床前阶段[170] 商业化合作 - 公司与Benuvia签订独家许可协议,获得三种非阿片类止痛喷雾剂的开发和商业化权利[176] - 公司将支付Benuvia6.5%的特许权使用费,并向其发行384,226股普通股[177] - 公司计划于2024年第三季度开始为这三种喷雾剂进行临床开发,并与FDA商讨505(b)(2)监管途径的具体要求[178] 财务状况 - 公司2024年上半年净亏损430万美元,较2023年同期增加86%,主要由于运营成本增加[192] - 公司一般及行政费用增加98%,主要包括薪酬、保险、IPO费用等的上升[194] - 研发费用增加103%,主要用于CMC服务[197] - 公司专业服务费用增加177%,主要为审计和法律费用[198] - 公司2024年6月30日现金余额240万美元,累计亏损1790万美元,存在持续经营的重大不确定性[201] - 公司预计未来12个月内研发费用约300万美元,将用于推进CC8464和CT2000项目[210] - 公司预计将继续产生重大和不断增加的费用和经营亏损,并预计在可预见的未来将继续产生经营亏损和负经营现金流[211] - 公司预计首次公开发行所得款项净额加上现有现金将足以为其运营和资本支出提供资金至2024年底,但也可能会提前耗尽资金[212]

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the "Board of Directors") has authorized a stock repurchase plan (the "Repurchase Plan") of up to $250,000 of Chromocell's common stock ("Common Stock"), which represents approximately 23% of the non-affiliate float based on the closing price of the Company's Co ...

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized a stock repurchase plan (the “Repurchase Plan”) of up to $250,000 of Chromocell’s common stock (“Common Stock”), which represents approximately 23% of the non-affiliate float based on the closing price of the Co ...

FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it will present at the Virtual Investor Lunch Break: The Chromocell Opportunity event on Thursday, July 18, 2024 at 12:00 PM ET. As part of the event, Frank Knuettel II, Chief Executive Officer and Chief Financial Officer of Chromocell, will provide a corporate overview and business ou ...

FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it will present at the Virtual Investor Lunch Break: The Chromocell Opportunity event on Thursday, July 18, 2024 at 12:00 PM ET. As part of the event, Frank Knuettel II, Chief Executive Officer and Chief Financial Officer of Chromocell, will provide a corporate overview and b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________to _______________. Commission File Number: 001-41964 Chromocell Therapeutics Corporation (Exact name of registrant as specified in its charter) D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 333-269188 Chromocell Therapeutics Corporation (Exact name of registrant as specified in its charter) Delaware 8 ...